Kwara is a company.
Kwara has raised $7.0M across 2 funding rounds.
Key people at Kwara.
Kwara has raised $7.0M in total across 2 funding rounds.
Key people at Kwara.
Kwara Chemical Company Limited is a Nigerian pharmaceutical manufacturer specializing in producing human and veterinary medicines such as anti-malaria drugs, analgesics, vitamins, and antibiotics. It serves primarily the Nigerian market, with a growing presence in northern Nigeria and expanding into the southwest, including Lagos and Ibadan. The company addresses the critical need for accessible, quality pharmaceutical products in Nigeria, leveraging modern, cGMP-compliant manufacturing facilities to ensure product safety and efficacy. Kwara Chemical has demonstrated steady growth by expanding its market reach and maintaining high-quality standards through rigorous quality assurance processes[1][2].
Founded in Ilorin, Kwara State, Kwara Chemical Company operates from a 10,000 sqm facility at No 3, Oko Erin Road. The company is managed by a team of qualified Nigerian professionals and governed by a board of eminent Nigerian directors, including Aremu Babs Yahaya and Funmilayo Taibat Yahaya. The company was established to meet Nigeria's pharmaceutical needs locally, reducing dependency on imports and improving drug availability. Early traction came from its registration and compliance with the Pharmaceutical Council of Nigeria (PCN) and the National Food and Drugs Administration and Control (NAFDAC), which helped build trust and credibility in the market[1].
While Kwara Chemical is primarily a pharmaceutical manufacturing company rather than a tech firm, it operates within Nigeria’s growing industrial and healthcare sectors, which are increasingly influenced by technological advancements in manufacturing and quality control. The company benefits from Nigeria’s broader push to develop local pharmaceutical production capabilities to reduce import reliance and improve healthcare outcomes. This aligns with national trends emphasizing self-sufficiency, industrialization, and healthcare innovation. Kwara Chemical’s role is crucial in strengthening Nigeria’s pharmaceutical supply chain and supporting public health infrastructure[1][2].
Kwara Chemical is well-positioned to capitalize on Nigeria’s expanding healthcare market and the government’s focus on local pharmaceutical production. Future growth may come from further geographic expansion, product diversification, and potential adoption of advanced manufacturing technologies. As Nigeria’s healthcare demands grow, Kwara Chemical’s commitment to quality and local production could enhance its market share and influence. The company’s trajectory reflects broader economic trends favoring indigenous manufacturing and healthcare accessibility, making it a key player in Nigeria’s pharmaceutical industry moving forward[1][2].
Kwara has raised $7.0M in total across 2 funding rounds.
Kwara's investors include Breega, Connect Ventures, Ameet Patel, BlueRun Ventures, Hack VC, Nyca Partners, Outrun Ventures, Jason Henrichs.
Kwara has raised $7.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2023 | $3.0M Seed | Breega, Connect Ventures, Ameet Patel | |
| Dec 1, 2021 | $4.0M Seed | BlueRun Ventures, Breega, Connect Ventures, Hack VC, Nyca Partners, Outrun Ventures, Ameet Patel, Jason Henrichs |
